Federal Register Notice: FDA has determined that the regulatory review period for Visudyne (verteporfin) is 3,194 days for extending a patent claiming that human drug product. Visudyne is indicated for treating age-related macular degeneration in patients with predominantly classic subfoveal choroidal neovascularization. To view this notice, click here.
